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Peripheral T-cell lymphoma (PTCL) is rare and diﬃcult to treat for its high relapse rate. The authors report a case of PTCL of
the skin, regarding which clinical and pathological features, treatment, and prognosis were discussed. A 66-year-old woman was
admitted with complaints of enlarging erythematous noduloplaques on the right anterior tibial skin for one year and similar
lesions on the left for 6 months. Surgical resection of right leg lesion and biopsy of enlarged inguinal lymph nodes histologically
indicated a PTCL of the nasal type. The patient was treated by CHOP plus bortezomib, reached complete remission just after two
courses of chemotherapy and then received another two as consolidation. The patient remained in remission for 11 months until
local relapse. As for cutaneous lesions, detailed lymph node examination and prompt tissue biopsy are judicious choices prior to
any medical management.The chemotherapy consisting of bortezomib and CHOP is safe and eﬃcient in PTCL of the skin.
1.Introduction
Peripheral T-cell lymphoma (PTCL), accounting for less
than 15% of non-Hodgkin’s lymphoma worldwide, derives
from natural killer or mature T cells (NK/TCL) and often
involves the skin primarily or secondarily [1]. PTCL has a
relatively higher morbidity rate in Asia and Central/South
America, especially in populations infected with human T-
celllymphoma/leukemiavirus-1orEpstein-Barrvirus(EBV)
[2]. Diagnosis in PTCL has improved with the development
of molecular, immunologic, and genetic techniques. How-
ever, there is still no consensus about standardized therapy
in PTCL, although CHOP (cyclophosphamide, pirarubicin,
vincristine, and prednisone) or CHOP-like chemotherapy
have been thought as the major regimen [3]. Progress in
treatment ofPTCL ismuch slow mainly due to disease rarity,
biological heterogeneity, geographic variation, and limited
recognition of the disease. To date, the prognosis of most
P T C Lt y p e si se x t r e m e l yp o o rw i t ha5 - y e a rs u r v i v a lo f1 5 –
30% in the majority of series [1]. Inrecent years, bortezomib
as a novel proteasome inhibitor, has shown good tolerance
and therapeutic eﬀect in PTCL besides deﬁned indications
for multiple myeloma and mantle cell lymphoma, which is
bringing new light to PTCL patients [4, 5].
Here, we present a case of peripheral NK/TCL of the
skin with positive EBV infection, in which bortezomib
plus CHOP chemotherapy were used and led to rapid
improvement and then complete remission (CR) for 11
months until local relapse. We also discussed the diagnosis,
prognosis, and bortezomib- or plus CHOP-based treatment
ofPTCLaccordingtothiscaseandpreviouslypublisheddata.
2.Case Report
In October 2007, a 66-year-old woman ﬁrstly visited a
dermatology clinic with chief complaints of erythematous
noduloplaques with mild tenderness and pitting edema on
the right anterior tibial skin. She was diagnosed with der-
matitis and continuously improved under infrared irradia-
tionuntil April2008,whensimilar dermaticlesionsoccurred
on the left anterior tibial area. In September 2008, the
reddish-violet noduloplaquesonboth legs increased to a size
of ahen’s egg, and the lesion on right leg even ulcerated and2 Case Reports in Medicine
Figure 1: Sections of invaded skin showing prominent inﬁltration
byperipheralnaturalkiller/T-celllymphomacells(hematoxylinand
eosin, ×400).
bled. The woman was then admitted to our hospital without
a history of fever or weight loss. Physical examination
showed multiple painless swollen lymph nodes of moderate
hardness and limited motion in bilateral inguinal areas,
which were assessed by color Doppler ultrasound with the
largestonebeing19 ×6micrometerinsize.Acomprehensive
metabolic proﬁle displayed an elevated serum level of lactate
dehydrogenase (LDH) of 256U/L (normal: 60 to 240U/l).
Computerized tomography scan of the chest and abdomen
was normal except for hepatic cysts.
The surgical resection and dermatoplasty of right leg
lesion and biopsy of homolateral inguinal lymph nodes were
carried out by plastic surgeons. Both the sections of invaded
skin and lymph nodes histologically indicated peripheral
NK/TCL of the nasal type with strongly positive CD56,
CD43, CD3 and Ki67, but negative CD20, CD30, Bcl-2,
and perforin by immunohistochemistry (Figures 1 and 2).
E B V - e n c o d e dR N A( E B E R )w a sp o s i t i v ei ns k i ns p e c i m e n
by in situ hybridization. Serum anti-EBV capsid antigen
(CA) IgM and antiearly antigen IgG were negative, but
antinuclear antigen-1 IgG, anti-CA IgG, and anti-CA IgA
were signiﬁcantly positive.
The patient underwent a combination chemother-
apy consisting of classical CHOP-21 plus bortezomib
(1.3mg/m2), which were administered by bolus injection
on days 1, 4, 8, and 11, every 21 days. Simultaneously,
acyclovir was intravenously used to protect against mucocu-
taneous infection with herpes simplex virus. The disease was
quickly and signiﬁcantly improved, which mainly displayed
in diminishing noduloplaques, shrinking erythemas and
swollen lymph nodes, decreasing edema, elimination of
tenderness, and normalization of local skin temperature.
She reached CR with mild brown pigmentation just after
two courses of chemotherapy and received another two
courses as consolidation (Figure 3). The therapy was well
tolerated with only grade-two toxicities of neutropenia and
thrombocytopenia.The patientremained in remission for11
months but relapsed locally and became lost to followup at
last.
3.Discussion
As for most PTCL patients with skin involvement but no B
symptoms, cutaneous lesions are always signiﬁcant enough
to be initially identiﬁed and treated as common dermatitis
at a dermatology clinic such as in this case. Detailed
physical examination, especially lymph node examination,
and prompt tissue biopsy are judicious choices prior to any
medical management in order to avoid misdiagnosis and
delay of correct treatment. Histologically, PTCL contains
multiple subtypes including PTCL unspeciﬁed (PTCL-U),
cutaneous TCL (CTCL), angioimmunoblastic TCL (AILT),
anaplastic large-cell lymphoma (ALCL) noncutaneous, and
hepatosplenic TCL (HSTCL) [2]. Adequate immunopheno-
typing is essential to exclude B-cell lymphomas and establish
the speciﬁc type of PTCL by immunohistochemistry or
ﬂow cytometry. In our case, the immunostaining results of
strongly positive CD3, CD43, CD56, and Ki67, but negative
CD20,CD30,andBcl-2,deﬁnitelysupportedthediagnosisof
peripheral NK/TCLofthe nasal type,although the negativity
for perforin is indeed unusual [6].
Up to now, there is no standard eﬃcient therapy
for PTCL [1]. CHOP-like treatment, as the most com-
monly used ﬁrst-line regimen for PTCL patients, is largely
ineﬀective with low CR and high relapse rate except in
anaplastic-lymphoma-kinase- (ALK)-positive ALCL [3, 7].
Some emerging evidence demonstrated that CHOP might
n o tb ea p p r o p r i a t ea sac h e m o t h e r a p yb a c k b o n ef o rP T C L
patients since anthracyclines perhaps cannot inﬂuence the
outcome, at least of PTCL-U [1, 8–10]. Previous data
also suggested that expression of P-glycoprotein in PTCL
possibly results in multidrug resistance to conventional
systemic therapy, at least partly [11]. Other regimens that
are more intensive than CHOP did not show any signiﬁcant
improvement in the overall survival of PTCL patients yet,
with the exception of ALCL [12].
Bortezomib exerts an antitumor activity mainly through
aﬀecting the ubiquitin-proteasome pathway subsequently
leading to inhibition of NF-κB and stabilization of proapop-
totic proteins such as P53, Bcl-2, Bim, Bik, and Noxa [13].
It has been reported that NF-κB plays a critical role in the
pathogenesis of CTCL, and that bortezomib can signiﬁcantly
cause NF-κB down-regulation and CTCL cell apoptosis
[14]. Therefore, bortezomib may play a special therapeutic
role and, at the same time, be safe from the emergence
of acute toxicity in some types of PTCL due to its basic
function mechanisms. As reported, an advanced HSTCL
patient of gamma/delta type remained almost in CR for 27
months after 4 cycles of bortezomib plus the modiﬁed high-
dose CHOP prior to autologous peripheral blood stem cell
transplantation [15]. A phase clinical trial has conﬁrmed
that bortezomib indeed is safe and has signiﬁcant single-
agent activity in inducing remission (67% overall response
rate, ORR), even CR (17%), in patients with relapsed or
refractory CTCLs including mycosis fungoides and PTCL-U
withisolatedskin involvement[4].The mentionedstudyalso
indicated that bortezomib leads to higher or at least compa-
rable ORR compared with published data on gemcitabine,
pegylated liposomal doxorubicin, 2-chlorodeoxyadenosine,Case Reports in Medicine 3
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Figure 2: Sections of invaded skin and lymph nodes displaying strongly positive CD3 (cytoplasmic) (a), CD56 (b), CD43 (c), and Ki67 (d),
but negative CD20 (e), CD30 (f), Bcl-2 (g), and perforin (h) by immunohistochemistry (×400).
(a) (b) (c)
(d) (e) (f)
Figure 3: Rapid remission in left leg lesions by bortezomib plus CHOP chemotherapy. (a) Day 0 in the ﬁrst course. (b) Day 5 in the ﬁrst
course. (c) Day 8 in the ﬁrst course. (d) Day 5 after the ﬁrst course. (e) Day 7 after the second course. (f) Day 7 after the fourth course.
or pentostatin. Another recent phase I study demonstrated
that PTCL patients consisting of PTCL-U, NK/TCL, ALCL,
and angioimmunoblastic lymphoproliferative disease gained
proﬁts from the bortezomib plus CHOP therapy, with
61.5% ORR and unconﬁrmed CR rates [5]. The combined
regimen just caused grade-4 neutropenia associated with
febrile episode in one patient and grade-one peripheral
sensory neuropathy in three patients, which indicated a good
tolerance.
It has been reported that PTCL-U presenting in the
skin has an unfavorable prognosis [16]. The outcome
of PTCL appears to be associated with the International
Prognostic Index (IPI), Prognostic Index for PTCL-U (PIT),
and the International peripheral T-cell lymphoma Project
score (IPTCLP), which are used for risk classiﬁcation and
response and survival prediction [3, 12, 17, 18]. In addition,
EBV is positive in about 40% of PTCL, and some case
series have reported that EBER-positive tumors have a worse
outcome [3, 19]. Our patient belongs to the subgroup of
high risk with bad prognosis because of poor prognostic
indexes due to multiple risk factors: >60 years of age, ECOG
performance status >2, late stage, elevated serum LDH,
number of extranodal sites of involvement >1, high Ki67
expression, and positive EBV infection [20, 21]. Anyway,4 Case Reports in Medicine
the adopted regimen showed enough safety and quickly led
to satisﬁed therapeutic eﬀects in this case. Therefore, the
bortezomib plusCHOPchemotherapy is safe and eﬃcient in
peripheral NK/TCL according to our case and the literature
review, although further large-sized clinical trials with long-
period followup are still needed.
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